https://www.selleckchem.com/products/SNS-032.html
05), and root resorption surface percentage (P .05). Relative to maxillae with PBS injections, maxillae with 20 μg exendin-4 injections had lower receptor activator of nuclear factor kappa-B ligand (RANKL) mRNA expression (P .05), TNF-α mRNA expression (P .05), and RANKL/osteoprotegerin (OPG) ratio (P .01). There were no differences in the expression of OPG mRNA. Exendin-4 inhibits orthodontic tooth movement. Therefore, additional attention is needed for orthodontic patients who receive exendin-4 for diabetes treatme
Like
Comment
Share
